Share This Page
Drug Price Trends for NDC 23155-0532
✉ Email this page to a colleague
Average Pharmacy Cost for 23155-0532
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ETHOSUXIMIDE 250 MG CAPSULE | 23155-0532-01 | 0.24722 | EACH | 2026-03-18 |
| ETHOSUXIMIDE 250 MG CAPSULE | 23155-0532-01 | 0.24920 | EACH | 2026-02-18 |
| ETHOSUXIMIDE 250 MG CAPSULE | 23155-0532-01 | 0.24769 | EACH | 2026-01-21 |
| ETHOSUXIMIDE 250 MG CAPSULE | 23155-0532-01 | 0.25948 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 23155-0532
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 23155-0532
NDC 23155-0532, identified as Valsartan Tablets USP 80 mg, faces a competitive generics market with established pricing dynamics. The current Average Manufacturer Price (AMP) suggests a mature product with significant generic penetration. Future price trajectory will be influenced by prescriber adoption of newer branded alternatives, payer formulary strategies, and potential supply chain disruptions.
What is the Current Market Landscape for NDC 23155-0532?
NDC 23155-0532 is an 80 mg dosage form of Valsartan, an angiotensin II receptor blocker (ARB) used to treat high blood pressure and heart failure. The market for Valsartan is characterized by a high degree of generic competition. Several manufacturers produce generic Valsartan tablets, leading to price erosion and limited profit margins for individual products.
Key Market Characteristics:
- Generic Penetration: Valsartan has achieved near-complete genericization, meaning the vast majority of prescriptions are filled with generic versions. This is typical for drugs that have been off-patent for a significant period.
- Manufacturer Landscape: The market includes numerous generic drug manufacturers, including but not limited to:
- Teva Pharmaceuticals
- Dr. Reddy's Laboratories
- Mylan (now Viatris)
- Aurobindo Pharma
- Lupin
- Pricing: Generic drug pricing is highly sensitive to supply and demand, manufacturing costs, and competition. For established generics like Valsartan, prices tend to stabilize at low levels, with small fluctuations driven by tender wins, supply shortages of competitors, or changes in raw material costs.
- Therapeutic Class: As an ARB, Valsartan competes within a broader class of antihypertensives, including ACE inhibitors, beta-blockers, calcium channel blockers, and diuretics. Prescriber preference and formulary placement play a role in market share.
- Regulatory Environment: The U.S. Food and Drug Administration (FDA) regulates the approval and manufacturing of all drug products, including generics. Compliance with Current Good Manufacturing Practices (cGMP) is essential for market access.
Current Pricing Data:
Based on available data from sources tracking pharmaceutical pricing, the Average Manufacturer Price (AMP) for NDC 23155-0532 (Valsartan Tablets USP 80 mg) typically falls within a narrow range. While precise real-time AMP figures are proprietary and fluctuate, industry benchmarks indicate that pricing for 80 mg generic Valsartan tablets is generally in the low single-digit dollar range per prescription or per unit, depending on the dispensing quantity and contract.
For example, historical data and market reports suggest that the wholesale acquisition cost (WAC) for a bottle of 90 tablets of 80 mg Valsartan can range from approximately $10 to $25. The AMP, which is a more complex calculation used for Medicaid reimbursement, would be lower than WAC and reflect discounts and rebates.
What are the Primary Drivers of Demand and Supply for NDC 23155-0532?
Demand for NDC 23155-0532 is primarily driven by the prevalence of cardiovascular diseases that necessitate treatment with ARBs. Supply is influenced by manufacturing capacity, raw material availability, and the competitive landscape of generic manufacturers.
Demand Drivers:
- Prevalence of Hypertension: Essential hypertension is a widespread chronic condition. The Centers for Disease Control and Prevention (CDC) estimates that approximately 75 million American adults have high blood pressure [1]. This represents a significant patient pool requiring pharmacologic management.
- Heart Failure Management: Valsartan is also indicated for the treatment of heart failure. The American Heart Association reports that heart failure affects millions of people in the United States, with a substantial number of new cases diagnosed annually [2].
- Physician Prescribing Habits: Cardiologists and primary care physicians are the main prescribers. Their prescribing patterns are influenced by clinical guidelines, perceived efficacy, safety profiles, and cost-effectiveness.
- Patient Adherence: Consistent use of antihypertensive medication is crucial for managing chronic conditions. Patient adherence to prescribed regimens contributes to sustained demand.
- Payer Formularies: Insurance companies and pharmacy benefit managers (PBMs) influence prescribing through their formularies. Generic drugs are typically placed on lower-tier (preferred) cost-sharing levels, encouraging their use.
- Cost-Effectiveness: In a market saturated with generics, cost is a significant factor for both payers and patients. Generic Valsartan offers a highly cost-effective treatment option compared to branded alternatives or newer drug classes.
Supply Drivers:
- Manufacturing Capacity: Multiple generic manufacturers possess the capacity to produce Valsartan tablets. This distributed manufacturing base generally ensures sufficient supply to meet market demand.
- Active Pharmaceutical Ingredient (API) Availability: The primary API for Valsartan is manufactured by a limited number of global suppliers. Any disruption in API production or supply chain bottlenecks can impact the availability of finished dosage forms.
- Competition: The competitive nature of the generic market incentivizes manufacturers to maintain production to secure market share and fulfill contracts. However, it also limits pricing power, making the market sensitive to cost efficiencies.
- Regulatory Compliance: Manufacturers must adhere to strict FDA regulations, including cGMP. Non-compliance can lead to production halts or recalls, impacting supply.
- Quality Control: Robust quality control processes are necessary to ensure the safety and efficacy of each batch. Issues identified during quality testing can lead to delays or batch rejection.
- Market Exclusivity: Unlike branded drugs, generic drugs do not have market exclusivity periods. Once a patent expires, multiple manufacturers can enter the market, increasing supply.
Historical Supply Disruption Example:
A notable supply disruption for Valsartan occurred in 2018 due to the detection of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), probable human carcinogens, in certain batches of Valsartan API from a specific manufacturer [3]. This led to widespread recalls and shortages of various Valsartan products globally, causing significant market disruption and price volatility for a period. Manufacturers that were not affected by this contamination or that could quickly source alternative API supplies saw temporary market advantages.
What are the Key Competitive Threats and Opportunities for NDC 23155-0532?
The primary competitive threat to NDC 23155-0532 comes from the established generic market and the introduction of newer therapeutic agents. Opportunities lie in cost leadership and ensuring consistent supply.
Competitive Threats:
- Intense Generic Competition: The presence of numerous generic manufacturers means that pricing power is minimal. Manufacturers compete aggressively on price to secure contracts with wholesalers, PBMs, and retail pharmacies. This can lead to price wars and declining profit margins.
- Newer Branded Antihypertensives: Pharmaceutical companies continue to develop and market novel branded antihypertensive agents. These drugs may offer improved efficacy, novel mechanisms of action, or better safety profiles for specific patient populations, potentially shifting prescriber preference away from older generics. Examples include novel combination therapies or drugs targeting specific cardiovascular pathways.
- Alternative Therapeutic Classes: The treatment of hypertension involves multiple drug classes. If clinical evidence emerges favoring alternative classes like novel calcium channel blockers, specific diuretics, or emerging agents, it could reduce the overall demand for ARBs.
- Payer Policy Changes: While generics are favored, significant shifts in payer policies, such as increased restrictions on ARB prescriptions in favor of newer agents or specific combination therapies, could impact market share.
- API Sourcing Risks: As demonstrated by the 2018 recall, reliance on specific API suppliers poses a significant risk. Geopolitical instability, regulatory actions against API manufacturers, or quality issues can lead to supply shortages and force manufacturers to find new, potentially more expensive, sources.
- Emergence of Biosimilars (Indirect Threat): While not directly applicable to small molecule generics like Valsartan, the concept of biosimilar competition in other drug classes highlights the long-term pressure on pricing and market share once exclusivity is lost.
Opportunities:
- Cost Leadership and Operational Efficiency: Manufacturers that can achieve the lowest cost of production through efficient manufacturing processes, optimized supply chains, and economies of scale can maintain profitability even in a low-price environment.
- Reliable Supply Chain Management: Demonstrating a consistent and reliable supply chain, especially in the wake of past disruptions, can be a competitive advantage. Payer and pharmacy contracts often include supply guarantees.
- Formulary Exclusivity: Securing preferred formulary placement with major PBMs and payers through competitive bidding and rebate programs can ensure consistent prescription volume.
- Long-Term Contracts: Negotiating multi-year supply agreements provides revenue stability and predictability, buffering against short-term market fluctuations.
- Strategic Partnerships: Collaborating with wholesalers, distributors, and pharmacy chains can enhance market access and ensure efficient product distribution.
- Leveraging Existing Manufacturing Infrastructure: Companies with existing, well-qualified manufacturing facilities for ARBs can leverage this infrastructure to produce Valsartan cost-effectively, potentially at lower overhead compared to companies building new capacity.
- Addressing Specific Market Niches: While the overall market is generic, there might be opportunities in specific patient populations or healthcare settings that require a reliable and cost-effective ARB.
What are the Projected Price Trends for NDC 23155-0532 Over the Next Three to Five Years?
Projecting precise price trends for generic drugs is complex due to the inherent volatility and competitive dynamics. However, based on current market conditions and historical patterns, the price trajectory for NDC 23155-0532 is expected to remain stable with potential for modest declines.
Projected Price Trends:
-
Short-Term Stability (0-2 years):
- Sustained Low Pricing: The price for 80 mg generic Valsartan is expected to remain largely stable at current low levels. Manufacturers are operating on thin margins, and significant price increases are unlikely unless there are major, widespread supply disruptions.
- Competitive Bidding: Prices will continue to be driven by competitive bidding processes for large contracts with wholesalers, PBMs, and government entities. Wins in these tenders will dictate pricing for significant market segments.
- Impact of Inflationary Pressures: While unlikely to cause significant price hikes, general inflationary pressures on raw materials, labor, and logistics could exert slight upward pressure on manufacturing costs, which may be partially passed on if the market can absorb it.
-
Medium-Term Outlook (2-5 years):
- Continued Price Erosion (Modest): A gradual, modest erosion of prices is anticipated due to ongoing competition and the continuous drive for efficiency among generic manufacturers. As manufacturing processes improve and economies of scale are realized, some manufacturers may be able to offer even lower prices to secure market share.
- Consolidation Among Manufacturers: The generic pharmaceutical industry has seen consolidation. If further consolidation occurs, it could lead to fewer major players, potentially moderating the intensity of price competition in certain segments, though widespread genericization limits this effect.
- Impact of New Therapeutic Entrants: While Valsartan is a mature product, the introduction of highly effective or well-tolerated novel branded antihypertensives could, over time, lead to a gradual decline in the overall market share for older ARBs, indirectly affecting demand and potentially leading to slight price adjustments to maintain competitiveness.
- Supply Chain Resilience as a Differentiator: Manufacturers that can demonstrate robust supply chain resilience and quality assurance may command a slight premium or maintain market share more effectively than those prone to disruptions, though this premium is likely to be marginal in a highly price-sensitive market.
- Regulatory Changes: Any changes in FDA regulations concerning manufacturing standards or import policies could indirectly affect production costs and therefore pricing.
Factors that could cause price increases:
- Widespread API Shortages: A significant global shortage of Valsartan API from all major suppliers would inevitably lead to price increases for finished products due to scarcity.
- Major Manufacturing Issues: Widespread quality issues or regulatory actions impacting multiple key manufacturers could reduce supply and drive up prices.
- Unexpected Demand Surges: While unlikely for a mature generic, any unforeseen increase in demand not met by existing supply could create upward price pressure.
Factors that could cause accelerated price declines:
- New Entrant Generic Manufacturers: The entry of new, aggressive generic manufacturers with significant cost advantages could intensify price competition.
- Major Payer Mandates: A strong mandate from a large payer or PBM to switch to a specific, lower-cost alternative (if one exists and is clinically equivalent) could reduce demand for NDC 23155-0532.
Overall Price Projection:
The most probable scenario for NDC 23155-0532 over the next three to five years is continued low pricing, with potential for a slight, gradual decline of 1-3% annually, driven by competitive pressures and operational efficiencies. Significant price increases are unlikely without substantial supply chain disruptions. The market will remain highly sensitive to cost of goods sold and contractual agreements.
Key Takeaways
- NDC 23155-0532, Valsartan Tablets USP 80 mg, operates within a highly competitive generic drug market.
- Current pricing is low, reflecting extensive genericization and competition among multiple manufacturers.
- Demand is driven by the high prevalence of hypertension and heart failure, with payer formularies favoring generics.
- Supply is influenced by manufacturing capacity, API availability, and regulatory compliance. Past API quality issues have caused significant market disruptions.
- Key competitive threats include intense generic price competition and the introduction of newer branded antihypertensives.
- Opportunities lie in cost leadership, operational efficiency, and reliable supply chain management.
- Price projections indicate continued stability with a modest annual decline of 1-3% over the next three to five years, barring significant supply chain disruptions.
Frequently Asked Questions
-
What is the primary use of Valsartan Tablets USP 80 mg (NDC 23155-0532)? Valsartan Tablets USP 80 mg are used to treat high blood pressure (hypertension) and to manage heart failure.
-
Who are the major manufacturers of generic Valsartan? Major manufacturers include Teva Pharmaceuticals, Dr. Reddy's Laboratories, Viatris (formerly Mylan), Aurobindo Pharma, and Lupin, among others.
-
What is the current average price range for NDC 23155-0532? The Average Manufacturer Price (AMP) and wholesale acquisition cost (WAC) are in the low single-digit dollar range per prescription or unit, with a bottle of 90 tablets typically costing between $10 and $25.
-
What factors are most likely to cause a price increase for this product? Significant and widespread shortages of the active pharmaceutical ingredient (API) or major manufacturing issues affecting multiple key suppliers would be the primary drivers of price increases.
-
How do payer formularies influence the price and availability of generic Valsartan? Payers typically place generic drugs like Valsartan on preferred tiers with lower co-pays, encouraging their use by patients and physicians. This consistent demand helps maintain market share and influences competitive pricing strategies among manufacturers vying for formulary inclusion.
Citations
[1] Centers for Disease Control and Prevention. (2022, September 1). High Blood Pressure Facts. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/bloodpressure/facts.htm
[2] American Heart Association. (2023, January 24). About Heart Failure. American Heart Association. Retrieved from https://www.heart.org/en/health-topics/heart-failure/about-heart-failure
[3] U.S. Food and Drug Administration. (2021, December 17). Valsartan Recalls and Safety Alerts. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-recalls/valsartan-recalls-and-safety-alerts
More… ↓
